PerkinElmer Q3 Revenue Up 10 Percent on Increased LAS Business
PerkinElmer said last week that increasing revenues in its Life and Analytical Sciences division offset lower biopharma receipts and helped the company post a 10-percent jump in third-quarter revenue.
Total receipts for the period ended Sept. 30 increased to $403 million from $366 million one year ago. Revenue from the company’s Life and Analytical Sciences division, which offers products for genetic screening, service, and environment, grew 4 percent, to $243.7 million from $235.1 million.
PerkinElmer’s life and analytical sciences business reported revenues of $244 million for the period, up from $235 million for the third quarter in 2003.
Research and development expenses were $21 million for the period, up from $20 million for the same quarter in 2003.
Net income during the quarter surged to $24 million, or $.19 per share, from $14 million, or $.11 per share, in the year-ago quarter.
The company reported cash and cash equivalents of $220 million on hand at the end of the quarter.
Beckman Q3 Revenue Up 8 Percent; Sales of Genomic, Proteomic Tools Strong
Beckman reported sales last week of $581 million for the third quarter, up over $535 million one year ago.
The company’s Biomedical Research Division, which sells the GenomeLab and ProteomeLab instruments, increased by 5 percent year over year. Clinical Diagnostics, by comparison, was up 10 percent.
R&D spending for the period increased to $51.5 million from $46.5 million. Net earnings for the quarter jumped to $57 million, or $.93 per basic earnings per share, from $40 million, or $.65 per basic earnings per share, for the same quarter in 2003.
The company reported cash and cash equivalents of $31 million on hand as of Sept. 30.
Hamilton and Kendro Form Partnership to Jointly Market Automated Solutions for Protein Crystallization
Swiss laboratory automation company Hamilton Bonaduz and Asheville, NC-based Kendro Laboratory Products have formed an alliance to market Rhombix system solutions for automated protein crystallization. Under the agreement, both companies will market and develop the Rhombix system and Rhombix series products.
“This new partnership will allow both companies to increase their strong positions in the fast-growing proteomics sector,” said Andreas Wieland, CEO of Hamilton.
The Rhombix system allows all partial steps in protein crystallization to be automated with a high level of reproducibility. The system requires a minimal amount of samples. It uses a database-driven informatics platform called the Centrix Automation Engine that tracks data flow and uses that data to optimize crystallization parameters in subsequent experiments.
Database integration of all components enables information on conditions under which crystals have grown to be evaluated in a simple, straightforward manner, the companies said.
GE Healthcare, Emerson Collaborate on Protein Purification Systems
The Emerson Process Management unit of electronics and appliance manufacturer Emerson have signed an agreement with GE Healthcare to integrate their technologies for protein purification.
Under the alliance, the firms will integrate Emerson’s digital process automation system with GE Healthcare’s chromatography and filtration control system software.
Terms of the alliance were not disclosed.
Nonlinear Dynamics, GenoLogics Partner On Protein Informatics
Nonlinear Dynamics and GenoLogics Life Sciences Software have formed a collaboration to develop a fully integrated protein informatics solution.
The firms intend to integrate Nonlinear Dynamics’ analysis and data mining expertise with GenoLogics’ laboratory information management system, the firms said in a press release issued today. Terms of the alliance were not disclosed.
Nonlinear Dynamics has developed ProMST, a system used for 2D gel-based sample and experimental data entry, mining stored analysis results and linking mass spec-based protein identities to 2D gel-based data. GenoLogics makes the ProteusLIMS, a proteomics-based laboratory information management system.
Compugen’s Q3 Revenues Slide As Company Refocuses; CEO to Step Down in 2005
Compugen has reported sliding revenues and increased losses for the third quarter, resulting from the discontinuation of certain products tied to the company’s new focus on diagnostics and drug discovery.
In addition, the company’s president and CEO, Mor Amitai, said he will step down by the end of next year. Amitai said is stepping down so that Compugen may hire a CEO with “more experience in pharmaceutical product development and commercialization.”
Compugen booked $1 million in revenues for the quarter ended Sept. 30, down from $2 million during the same period last year.
R&D expenses decreased slightly to $2.8 million, from $3.1 million during the same quarter in 2003.
The company’s net loss widened to $3.6 million, or $.13 per share, from $3.2 million, or $.12 per share, during the year-ago quarter.
“These results reflect the implementation of the company’s previously announced decision to focus on diagnostic and therapeutic discovery and related intellectual property based commercialized and alliances,” Compugen said in a statement.
As of Sept. 30, Compugen had $25 million in cash, cash equivalents, short-term cash deposits, and short-term marketable securities.